Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 5,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

NCT06367738
View directory record Official record
Conditions
Aging
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

BMAC & Allograft vs BMP-2

NCT02924571
View directory record Official record
Conditions
Spinal Fusion
Interventions
Bone Marrow Aspirate Concentrate (BMAC) + Allograft, Recombinant Human Bone Morphogenetic Protein-2 (BMP), Autograft
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 22, 2026, 6:42 AM EDT
Withdrawn Phase 1 Interventional

A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis

NCT00679744
View directory record Official record
Conditions
G(M2) Ganglioside, Tay-Sachs Disease Ganglioside, Sandhoff Disease Ganglioside
Interventions
Pyrimethamine
Drug
Lead sponsor
Exsar Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 22, 2026, 6:42 AM EDT
Terminated Phase 1 Interventional

Melphalan With BBBD in Treating Patients With Brain Malignancies

NCT00253721
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
Interventions
Melphalan
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

Web-Based Program for Symptom Management in Fibromyalgia

NCT02515552
View directory record Official record
Conditions
Fibromyalgia
Interventions
The Fibromyalgia Wellness Project
Behavioral
Lead sponsor
Collinge and Associates, Inc.
Other
Eligibility
21 Years and older
Enrollment
883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 22, 2026, 6:42 AM EDT
Terminated Phase 1 Interventional

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

NCT04432207
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
Interventions
IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3, Atezolizumab, Standard of care chemotherapy
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Comparing Effects of 3 Sources of Garlic on Cholesterol Levels

NCT00056511
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Fresh garlic or garlic supplements
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
30 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 22, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

NCT07179614
View directory record Official record
Conditions
Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders
Interventions
Overdose Prevention Intervention Package (OPIP)
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Barbourville, Kentucky • Harlan, Kentucky • Hyden, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 6:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

NCT02908906
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-63723283
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

NCT00722384
View directory record Official record
Conditions
Macular Degeneration
Interventions
bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2008 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

NCT00458952
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace Iobenguane (MIBG) I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 22, 2026, 6:42 AM EDT
Active, not recruiting Not applicable Interventional

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

NCT04809714
View directory record Official record
Conditions
Hip Fractures, Muscle Atrophy
Interventions
Blood Flow Restriction with Delfi Tourniquet System Cuff, Routine Post-operative Physical Therapy
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Early Phase 1 Interventional

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

NCT03272568
View directory record Official record
Conditions
Hemophilia, Menstrual Flow Excessive
Interventions
Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 22, 2026, 6:42 AM EDT
Recruiting Phase 1 Interventional

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

NCT05526924
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancers - Throat
Interventions
Chemoradiation, Pamiparib, Hydroxyurea, Fluorouracil (5FU), Tislelizumab
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 6:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PKU Skin Stripping

NCT04368624
View directory record Official record
Conditions
Phenylketonurias
Interventions
Skin Tape, Blood Draw
Other · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 22, 2026, 6:42 AM EDT
Recruiting Not applicable Interventional

Factors in Learning And Plasticity: Macular Degeneration

NCT05454124
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Training visual sensitivity, Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 22, 2026, 6:42 AM EDT
Terminated Phase 1 Interventional

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

NCT02283359
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Selinexor, Irinotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 22, 2026, 6:42 AM EDT
Not listed No phase listed Observational

Emulated Study of Vitamin D Correction Vs Non-Correction

NCT06366776
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Not listed
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Treatment of POEMS Syndrome With Daratumumab

NCT04396496
View directory record Official record
Conditions
POEMS Syndrome
Interventions
Daratumumab Injection
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors

NCT01310179
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Ad/PNP and fludarabine monophosphate
Genetic
Lead sponsor
PNP Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 22, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

NCT03326583
View directory record Official record
Conditions
ESRD, Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer
Drug
Lead sponsor
Dominic Raj
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 6:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults (The Exergames Telerehabilitation Study)

NCT06340659
View directory record Official record
Conditions
At Risk for AD-dementia, With Subjective Cognitive Decline
Interventions
HbAEx, HbExergame
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 6:42 AM EDT